<p>在最近的三個月中，11 位分析師分享了他們對 WAVE Life Sciences（納斯達克：WVE）的見解，表達了從看漲到看跌的各種觀點。</p>
<p>在下面的表格中，您將找到他們最近評級的摘要，揭示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師提供了更深入的見解，設定了 12 個月的價格目標，顯示出平均目標為 37.27 美元，最高估計為 52.00 美元，最低估計為 27.00 美元。當前平均價格目標較之前的 30.00 美元上升了 24.23%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773165696_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773165696_0.png"/></p>
<h2>分析分析師評級：詳細拆解</h2>
<p>金融專家對 WAVE Life Sciences 的看法通過最近的分析師行動進行了分析。以下摘要展示了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上調</td>
<td>買入</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上調</td>
<td>超越市場</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>維持</td>
<td>買入</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>超配</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steve Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>上調</td>
<td>超配</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上調</td>
<td>買入</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>上調</td>
<td>買入</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Cheng Li</td>
<td>Oppenheimer</td>
<td>上調</td>
<td>超越市場</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>上調</td>
<td>買入</td>
<td>$37.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上調</td>
<td>超越市場</td>
<td>$33.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化做出反應，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 WAVE Life Sciences 近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師從定性角度評估股票，評級範圍從 “超越市場” 到 “表現不佳”。這些評級傳達了對 WAVE Life Sciences 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師通過調整價格目標，提供 WAVE Life Sciences 未來價值的估計。比較當前和之前的目標提供了分析師期望變化的見解。</li>
</ul>
<p>為了獲取 WAVE Life Sciences 市場表現的有價值見解，請考慮將這些分析師評估與關鍵財務指標結合使用。保持信息靈通，做出明智的決策，使用我們的評級表。</p>
<p>隨時瞭解 WAVE Life Sciences 的分析師評級。</p>
<h2>關於 WAVE Life Sciences 的所有信息</h2>
<p>WAVE Life Sciences Ltd 是一家臨牀階段的生物技術公司，專注於開發 RNA 藥物（也稱為寡核苷酸），旨在轉變人類健康。RNA 藥物平台 PRISM 結合了多種模式、化學創新和對人類遺傳學的深入洞察，以提供科學突破，治療罕見和常見疾病。其 RNA 靶向工具包包括 RNA 編輯、反義沉默和 RNA 干擾，提供設計和可持續交付候選藥物的能力，以最佳方式應對疾病生物學。其項目針對罕見和常見疾病，包括α-1 抗胰蛋白酶缺乏症、肥胖、杜氏肌營養不良和亨廷頓病。</p>
<h3>關鍵指標：WAVE Life Sciences 的財務健康</h3>
<p><strong>市值分析：</strong> 反映出公司規模較小，其市值低於行業平均水平。這可能歸因於增長預期或運營能力等因素。</p>
<p><strong>收入下降：</strong> 在過去的 3 個月中，WAVE Life Sciences 面臨挑戰，導致截至 2025 年 12 月 31 日收入增長約下降 <strong>-79.41%</strong>。這意味着公司的收入出現了減少。與醫療保健行業的其他公司相比，該公司的增長率低於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> 公司的淨利潤率低於行業基準，表明在實現強勁盈利能力方面可能面臨困難。淨利潤率為 <strong>-308.37%</strong>，公司可能需要解決有效成本控制方面的挑戰。</p>
<p><strong>股本回報率（ROE）：</strong> WAVE Life Sciences 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-16.54%</strong>，公司可能在實現最佳財務回報方面面臨障礙。</p>
<p><strong>資產回報率（ROA）：</strong> 公司的 ROA 低於行業基準，表明在有效利用資產方面可能面臨困難。ROA 為 <strong>-12.09%</strong>，公司可能需要解決從其資產中產生滿意回報的挑戰。</p>
<p><strong>債務管理：</strong> WAVE Life Sciences 的債務與股本比率為 <strong>0.03</strong>，低於行業平均水平，反映出對債務融資的依賴較低，採取了更為保守的財務策略。</p>
<h2>分析師評級是如何確定的？</h2>
<p>Benzinga 跟蹤 150 家分析師公司並報告他們對股票的預期。分析師通常通過預測公司未來的盈利能力，通常是未來五年，以及該公司收入來源的風險性或可預測性來得出結論。</p>
<p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或者在公司有重大更新時進行評級。</p>
<p>分析師可能通過納入增長預期、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們也是人，在提供見解時會表達自己的觀點。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

生物技術臨牀實驗 ETF - LifeSci

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

WAVE生命科學

標普生物技術 ETF - SPDR

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

<p>WAVE Life Sciences（納斯達克代碼：WVE）在過去三個月中獲得了 11 位分析師的混合評級，平均 12 個月目標價為 37.27 美元，較之前的目標價上漲了 24.23%。分析師們提高或維持了他們的評級，其中 Canaccord Genuity 和 HC Wainwright & Co.等公司的評級顯著上調。然而，該公司面臨挑戰，包括 79.41% 的收入增長下降和負淨利潤率。WAVE Life Sciences 專注於 RNA 藥物，且其保守的債務與股本比率為 0.03，表明其對債務融資的依賴較低</p>

<p>Across the recent three months, 11 analysts have shared their insights on WAVE Life Sciences (NASDAQ: WVE), expressing a variety of opinions spanning from bullish to bearish.</p>
<div class="lb-trans"><p>在最近的三個月中，11 位分析師分享了他們對 WAVE Life Sciences（納斯達克：WVE）的見解，表達了從看漲到看跌的各種觀點。</p>
</div><p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<div class="lb-trans"><p>在下面的表格中，您將找到他們最近評級的摘要，揭示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.27, along with a high estimate of $52.00 and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 24.23% from the previous average price target of $30.00.</p>
<div class="lb-trans"><p>分析師提供了更深入的見解，設定了 12 個月的價格目標，顯示出平均目標為 37.27 美元，最高估計為 52.00 美元，最低估計為 27.00 美元。當前平均價格目標較之前的 30.00 美元上升了 24.23%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773165696_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1773165696_0.png"/></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<div class="lb-trans"><h2>分析分析師評級：詳細拆解</h2>
</div><p>The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>金融專家對 WAVE Life Sciences 的看法通過最近的分析師行動進行了分析。以下摘要展示了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steve Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Cheng Li</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上調</td>
<td>買入</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上調</td>
<td>超越市場</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>維持</td>
<td>買入</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>超配</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steve Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>上調</td>
<td>超配</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上調</td>
<td>買入</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>上調</td>
<td>買入</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Cheng Li</td>
<td>Oppenheimer</td>
<td>上調</td>
<td>超越市場</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>上調</td>
<td>買入</td>
<td>$37.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上調</td>
<td>超越市場</td>
<td>$33.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to WAVE Life Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for WAVE Life Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化做出反應，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 WAVE Life Sciences 近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師從定性角度評估股票，評級範圍從 “超越市場” 到 “表現不佳”。這些評級傳達了對 WAVE Life Sciences 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師通過調整價格目標，提供 WAVE Life Sciences 未來價值的估計。比較當前和之前的目標提供了分析師期望變化的見解。</li>
</ul>
</div><p>For valuable insights into WAVE Life Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了獲取 WAVE Life Sciences 市場表現的有價值見解，請考慮將這些分析師評估與關鍵財務指標結合使用。保持信息靈通，做出明智的決策，使用我們的評級表。</p>
</div><p>Stay up to date on WAVE Life Sciences analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 WAVE Life Sciences 的分析師評級。</p>
</div><h2>All You Need to Know About WAVE Life Sciences</h2>
<div class="lb-trans"><h2>關於 WAVE Life Sciences 的所有信息</h2>
</div><p>WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.</p>
<div class="lb-trans"><p>WAVE Life Sciences Ltd 是一家臨牀階段的生物技術公司，專注於開發 RNA 藥物（也稱為寡核苷酸），旨在轉變人類健康。RNA 藥物平台 PRISM 結合了多種模式、化學創新和對人類遺傳學的深入洞察，以提供科學突破，治療罕見和常見疾病。其 RNA 靶向工具包包括 RNA 編輯、反義沉默和 RNA 干擾，提供設計和可持續交付候選藥物的能力，以最佳方式應對疾病生物學。其項目針對罕見和常見疾病，包括α-1 抗胰蛋白酶缺乏症、肥胖、杜氏肌營養不良和亨廷頓病。</p>
</div><h3>Key Indicators: WAVE Life Sciences's Financial Health</h3>
<div class="lb-trans"><h3>關鍵指標：WAVE Life Sciences 的財務健康</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 反映出公司規模較小，其市值低於行業平均水平。這可能歸因於增長預期或運營能力等因素。</p>
</div><p><strong>Decline in Revenue:</strong> Over the 3M period, WAVE Life Sciences faced challenges, resulting in a decline of approximately <strong>-79.41%</strong> in revenue growth as of 31 December, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入下降：</strong> 在過去的 3 個月中，WAVE Life Sciences 面臨挑戰，導致截至 2025 年 12 月 31 日收入增長約下降 <strong>-79.41%</strong>。這意味着公司的收入出現了減少。與醫療保健行業的其他公司相比，該公司的增長率低於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-308.37%,</strong> the company may need to address challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 公司的淨利潤率低於行業基準，表明在實現強勁盈利能力方面可能面臨困難。淨利潤率為 <strong>-308.37%</strong>，公司可能需要解決有效成本控制方面的挑戰。</p>
</div><p><strong>Return on Equity (ROE):</strong> WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-16.54%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> WAVE Life Sciences 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-16.54%</strong>，公司可能在實現最佳財務回報方面面臨障礙。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-12.09%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 公司的 ROA 低於行業基準，表明在有效利用資產方面可能面臨困難。ROA 為 <strong>-12.09%</strong>，公司可能需要解決從其資產中產生滿意回報的挑戰。</p>
</div><p><strong>Debt Management:</strong> WAVE Life Sciences's debt-to-equity ratio is below the industry average at <strong>0.03</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> WAVE Life Sciences 的債務與股本比率為 <strong>0.03</strong>，低於行業平均水平，反映出對債務融資的依賴較低，採取了更為保守的財務策略。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析師評級是如何確定的？</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟蹤 150 家分析師公司並報告他們對股票的預期。分析師通常通過預測公司未來的盈利能力，通常是未來五年，以及該公司收入來源的風險性或可預測性來得出結論。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或者在公司有重大更新時進行評級。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析師可能通過納入增長預期、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們也是人，在提供見解時會表達自己的觀點。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

benzinga_article

WAVE 生命科學股票：深入探討分析師觀點（11 個評級）